Medicus Pharma's Skin Cancer Drug Achieves 73% Clinical Clearance in Positive Phase 2 Trial
Summary
Medicus Pharma reported positive topline Phase 2 results for its Doxorubicin Microneedle Array (D-MNA) (SKNJCT-003) for basal cell carcinoma, with the 200µg cohort demonstrating 73% clinical clearance and 40% histological clearance at Day 57. These "decision-grade" results are a significant de-risking event for the small-cap biotech, validating its scientific thesis and strengthening its position for an end-of-Phase 2 (EOP2) meeting with the FDA. This positive development is particularly important given the company's recent $15.3M at-the-market offering and a "going concern" warning earlier this year, as strong clinical data can attract partners and alleviate capital concerns. Investors should monitor the final Clinical Study Report (CSR) expected in Q2 2026, the outcome of the EOP2 meeting, and any potential strategic partnerships or licensing deals.
At the time of this announcement, MDCX was trading at $1.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $35.3M. The 52-week trading range was $0.92 to $8.94. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.